Evaluation of a New Anti-cancer Vaccine for Patients With Non-small Cell Lung Cancer, After Tumor Removal by Surgery

Lung Cancer, Non-Small Cell Clinical Trial

Official title:

Study of GSK2302032A Antigen-Specific Cancer Immunotherapeutic in Patients With Resectable Non-Small Cell Lung Cancer

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01159964
• Other study ID #: 113174
• Status: Terminated
• Phase: Phase 1
• Start date: July 20, 2010
• Est. completion date: September 10, 2014

Study information

• Verified date: June 2018
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this clinical study is to assess the safety and immunogenicity of the immunotherapeutic product GSK 2302032A when given to Non-Small Cell Lung Cancer (NSCLC) patients, after tumor removal by surgery.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 60
• Est. completion date: September 10, 2014
• Est. primary completion date: October 19, 2011
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male or female patient with completely resected (R0 resection), pathologically proven stage IB, II or IIIA NSCLC. Patients are allowed to receive adjuvant platinum-based chemotherapy for the treatment of the current NSCLC between surgery and enrolment.

2. Written informed consent for PRAME gene expression screening on resected tumor tissue has been obtained from the patient prior to shipment of the sample for expression testing, and written informed consent for the complete study participation has been obtained before the performance of any other protocol specific procedure.

3. Patient is >= 18 years of age at the time of signature of the first informed consent form.

4. The patient's tumor shows expression of the PRAME gene.

5. The surgical technique for resection of the patient's tumor is anatomical, involving at least a lobectomy or a sleeve lobectomy. The first ASCI administration will be given, either within 12 weeks after surgery or within 8 weeks after day 1 of last chemotherapy cycle and within 32 weeks after resection.

6. The patient is free of metastasis, as confirmed by a negative baseline computer tomogram (CT scan) of the chest and upper abdomen as well as CT scan or magnetic resonance imaging (MRI) of the brain. These tests are to be performed within 6 weeks for the CT scan of the chest and upper abdomen and within 12 weeks for the brain CT scan or MRI before first ASCI administration.

7. ECOG performance status of 0, 1 or 2.

8. Adequate bone-marrow reserve, renal, adrenal and hepatic function as assessed by standard laboratory criteria

9. Female patients of non-childbearing potential may be enrolled in the study. Non-childbearing potential is defined as current tubal-ligation, hysterectomy, ovariectomy or post-menopause.

10. Female patient of childbearing potential may be enrolled in the study, if the patient:

• has practiced adequate contraception for 30 days prior to study product administration, and

• has a negative pregnancy test on the day of administration, and

• has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the study product administration series.

11. In the view of the investigator, the patient can and will comply with the requirements of the protocol.

Exclusion Criteria:

1. The primary tumor was removed by segmentectomy or wedge resection.

2. The patient has received any anti-cancer specific treatment, including radiotherapy, immunotherapy, chemotherapy or neo-adjuvant chemotherapy, except for the treatment of previous malignancies allowed by the protocol.

3. The patient requires concomitant treatment (more than 7 consecutive days) with systemic corticosteroids or any other immunosuppressive agents.

4. Use of any investigational or non-registered product (drug or vaccine, except influenza vaccine in the context of H1N1 mass-vaccination) other than the study product within the 30 days preceding the first dose of study product, or planned use during the study period.

5. The patient has previous or concomitant malignancies at other sites, except effectively treated non-melanoma skin cancers or carcinoma in situ of the cervix or effectively treated malignancy that has been in remission for more than 3 years and highly likely to have been cured.

6. History of allergic disease or reactions likely to be exacerbated by any component of the study investigational product.

7. History of confirmed adrenal dysfunction.

8. The patient has an autoimmune disease such as, but not limited to, multiple sclerosis, lupus, and inflammatory bowel disease. Patients with vitiligo are not excluded.

9. The patient has received a major organ allograft.

10. The patient is known to be Human Immunodeficiency Virus (HIV) -positive.

11. The patient has an uncontrolled bleeding disorder.

12. The patient has uncontrolled congestive heart failure or uncontrolled hypertension, unstable heart disease (coronary artery disease or myocardial infarction) or uncontrolled arrhythmia at the time of enrolment.

13. The patient needs home oxygenation.

14. The patient has psychiatric or addictive disorders that may compromise his/her ability to give informed consent, or to comply with the trial procedures.

15. The patient has other concurrent severe medical problems, unrelated to the malignancy, that would significantly limit full compliance with the study or expose the patient to unacceptable risk.

16. For female patients: the patient is pregnant or lactating.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Cancer, Non-Small Cell
• Lung Neoplasms

Intervention

Biological:
• Immunotherapeutic GSK2302032A, different formulations
Intramuscular administration

Locations

Country	Name	City	State
France	GSK Investigational Site	Montpellier
France	GSK Investigational Site	Nice
France	GSK Investigational Site	Paris Cedex 12
France	GSK Investigational Site	Toulouse
Germany	GSK Investigational Site	Berlin
Germany	GSK Investigational Site	Freiburg	Baden-Wuerttemberg
Germany	GSK Investigational Site	Heidelberg	Baden-Wuerttemberg
Germany	GSK Investigational Site	Immenhausen	Hessen
Germany	GSK Investigational Site	Koeln	Nordrhein-Westfalen
Germany	GSK Investigational Site	Leipzig	Sachsen
Germany	GSK Investigational Site	Moers	Nordrhein-Westfalen
Germany	GSK Investigational Site	Muenchen	Bayern
Germany	GSK Investigational Site	Regensburg	Bayern
Germany	GSK Investigational Site	Regensburg	Bayern
Germany	GSK Investigational Site	Velbert	Nordrhein-Westfalen
Italy	GSK Investigational Site	Meldola (FC)	Emilia-Romagna
Italy	GSK Investigational Site	Milano	Lombardia
Italy	GSK Investigational Site	Perugia	Umbria
Italy	GSK Investigational Site	Pisa	Toscana
Italy	GSK Investigational Site	Roma	Lazio
Poland	GSK Investigational Site	Checiny
Poland	GSK Investigational Site	Lublin
Poland	GSK Investigational Site	Szczecin
Poland	GSK Investigational Site	Warszawa
Poland	GSK Investigational Site	Zakopane
Russian Federation	GSK Investigational Site	Chelyabinsk
Russian Federation	GSK Investigational Site	Kazan
Russian Federation	GSK Investigational Site	Moscow
Russian Federation	GSK Investigational Site	St. Petersburg
Russian Federation	GSK Investigational Site	St. Petersburg
United States	GSK Investigational Site	Boston	Massachusetts
United States	GSK Investigational Site	Everett	Washington
United States	GSK Investigational Site	New York	New York
United States	GSK Investigational Site	Newark	Delaware
United States	GSK Investigational Site	Philadelphia	Pennsylvania
United States	GSK Investigational Site	Rochester	Minnesota
United States	GSK Investigational Site	Seattle	Washington

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Countries where clinical trial is conducted

United States,  France,  Germany,  Italy,  Poland,  Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Occurrence of dose-limiting toxicities during study treatment		During the study treatment period (up to 112 weeks, approximately 2 years and 2 months)
Primary	Occurrence of dose-limiting toxicities during study follow-up		12 months after concluding visit (week 112)
Primary	Anti-PRAME humoral immune response		Assessed post-dose 4 (Week 12)
Primary	Anti-PRAME humoral immune response		Throughout the study (Day 0 until 12 months after concluding visit (week 112))
Secondary	Occurrence of adverse events (AEs) and serious adverse events		During the whole study treatment period until 30 days after the last treatment administration.
Secondary	The anti-PRAME cellular (T-cell) response		At 6 defined time-points during the study (Week 0, 12, 24, 72 and 112) and follow-up period (6 months later).
Secondary	The anti-PRAME humoral immunogenicity		At 10 defined timepoints during the study (Week 0, 6, 12, 24, 48, 72, 96, 112), and follow-up period (6 and 12 months later).

External Links

•   Results for study 113174 can be found on the GSK Clinical Study Register